Insider Selling: Vor Biopharma (NASDAQ:VOR) Major Shareholder Sells 25,717 Shares of Stock

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 25,717 shares on October 17th for $30.25 each, totaling approximately $777,939.25, reducing their position by 2.14%.
• Vor Biopharma's stock price fell 5.6% to $27.77 amidst trading, significantly below its 52-week high of $65.80.
• Analysts have mixed views on Vor Biopharma, with ratings ranging from a strong sell to outperform, and an average target price of $77.83.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 25,717 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $30.25, for a total transaction of $777,939.25. Following the transaction, the insider directly owned 1,178,725 shares of the company's stock, valued at $35,656,431.25. The trade was a 2.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 21st, Reprogrammed Interchange Llc sold 200 shares of Vor Biopharma stock. The stock was sold at an average price of $30.07, for a total transaction of $6,014.00.
• On Monday, October 20th, Reprogrammed Interchange Llc sold 11,616 shares of Vor Biopharma stock. The stock was sold at an average price of $30.05, for a total transaction of $349,060.80.
• On Thursday, October 16th, Reprogrammed Interchange Llc sold 2,021 shares of Vor Biopharma stock. The stock was sold at an average price of $30.45, for a total transaction of $61,539.45.
• On Wednesday, October 15th, Reprogrammed Interchange Llc sold 71,655 shares of Vor Biopharma stock. The stock was sold at an average price of $31.92, for a total transaction of $2,287,227.60.
• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total transaction of $1,020,813.76.
• On Monday, October 13th, Reprogrammed Interchange Llc sold 22,006 shares of Vor Biopharma stock. The stock was sold at an average price of $32.44, for a total transaction of $713,874.64.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The stock was sold at an average price of $30.97, for a total transaction of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total transaction of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total transaction of $934,796.16.

Vor Biopharma Stock Down 5.6%

VOR stock traded down $1.66 during midday trading on Tuesday, hitting $27.77. The company's stock had a trading volume of 348,840 shares, compared to its average volume of 394,637. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80. The company has a market cap of $190.22 million, a price-to-earnings ratio of -0.10 and a beta of 2.07. The firm has a 50-day moving average of $36.24.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Money Concepts Capital Corp raised its holdings in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. XTX Topco Ltd acquired a new stake in Vor Biopharma during the 2nd quarter worth $66,000. Goldman Sachs Group Inc. raised its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. Ariose Capital Management Ltd acquired a new stake in Vor Biopharma during the 3rd quarter worth $5,368,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Vor Biopharma during the 1st quarter worth $100,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Zacks Research cut shares of Vor Biopharma from a "hold" rating to a "strong sell" rating in a research report on Monday, October 13th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Vor Biopharma in a research report on Thursday, August 14th. Robert W. Baird upgraded shares of Vor Biopharma from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $20.00 to $64.00 in a report on Wednesday, October 15th. Finally, Wall Street Zen lowered shares of Vor Biopharma to a "strong sell" rating in a report on Saturday, June 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Vor Biopharma currently has an average rating of "Hold" and a consensus target price of $77.83.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.